News and Events

IMPORTANT: HIV & RespiDART 2020 Virtual Conference

news

Subject: HIV & RespiDART 2020 virtual conference

 

Free registration is now open for HIV & RespiDART 2020 virtual conference. The primary focus of HIV DART (Day 1; December 10, 2020) will be on new advances in HIV cure strategies and injectable therapeutics development. RespiDART (Day 2, December 17, 2020) will focus on scientific advances in therapeutics and vaccines development for SARS-CoV-2.

More information on HIV & RespiDART 2020 can be found through the meeting website.

Tags: 
Publication Date: 
11/18/2020

Guia del CDC para la Celebración del Día de Acción de Gracias - Guide for Celebrating Thanksgiving

NEWS

Celebrating Thanksgiving – Updated Nov. 10, 2020

Languages:     English Link: https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/holidays/tha...

                       Spanish Link: https://espanol.cdc.gov/coronavirus/2019-ncov/daily-life-coping/holidays... (ver al abajo)

Traditional Thanksgiving gatherings with family and friends are fun but can increase the chances of getting or spreading COVID-19 or the flu. Follow these tips to make your Thanksgiving holiday safer.

The safest way to celebrate Thanksgiving this year is to celebrate with people in your household. If you do plan to spend Thanksgiving with people outside your household, take steps to make your celebration safer.

 

ESPAÑOL

Celebración del Día de Acción de Gracias

Los tradicionales encuentros el Día de Acción de Gracias con familiares y amigos son divertidos, pero pueden aumentar las posibilidades de contraer o propagar el COVID-19 o la influenza. Siga estos consejos para celebrar el Día de Acción de Gracias en forma segura.

La manera más segura de celebrar el Día de Acción de Gracias es hacerlo con los miembros de su hogar. Si planea celebrar el Día de Acción de Gracias con personas con las que no convive, tome medidas para que la celebración sea lo más segura posible.

Publication Date: 
11/12/2020

COVID-19 Roundtable Discussion

NEWS

COVID-19 Roundtable Discussion

 

On November 18, I will be hosting Technology Networks first virtual roundtable discussion,

COVID-19: Immune Response and Vaccine Efficacy. I will be joined by

Dr Anna Blakney, Imperial College London
Professor Benjamin tenOever, Icahn School of Medicine at Mount Sinai
Dr Jason Kindrachuk, Assistant Professor of University of Manitoba.
The panel will be exploring our understanding of SARS-CoV-2 and our body’s response to infection, as well as considering how these findings will impact the development of effective vaccines against COVID-19.

 

You can register for free here.

 

Have a question for our panel? Register today to submit a question.

Not able to attend on November 18? Register now and we will give you full access to the archived roundtable discussion as soon as it becomes available.

Best regards,

Ruairi MacKenzie
Science Writer

Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | Suffolk | CO10 0FD | UK
Email: privacy@technologynetworks.com

 

 

Publication Date: 
11/04/2020

IMPORTANTE: 3er Panel: UPR investiga el COVID-19

NEWS

CRiiAS le invita a participar del tercer panel La Universidad de Puerto Rico investiga el COVID-19, a llevarse a cabo el martes, 17 de noviembre de 2020 de 4:00pm-6:00pm en donde estaremos dando a conocer la gesta científica que ocurre en nuestra institución relacionado al COVID-19.

 

Los temas e invitados especiales de la actividad son:

 

Host-genetic susceptibility to COVID-19 and pandemic-associated stressors

 

Dra. María del Mar González

Catedrática Auxiliar

Centro Comprensivo del Cáncer

División de Biología del Cáncer

UPR-Recinto de Ciencias Médica

 

 

 

Pilot Cohort study of SARS-CoV-2 incidence, transmission and symptom severity in high-risk groups

in Puerto Rico

Dra. Filipa Godoy, PhD

Catedrática Asociada y Directora Interina

Departamento de Microbiología y Zoología Médica

Investigadora Principal

Laboratorio de Microbiomas

UPR-Recinto de Río Piedras

 

 

Dra. Josefina Romaguera, MD, MPH

Catedrática

Departamento de Obstetricia y Ginecología

Escuela de Medicina

UPR-Recinto de Ciencias Médicas

 

 

Puerto Rico Epidemiological Evaluation and Prevention of COVID-19 and Influenza (PREPCOVI)

 

Dra. Carlamarie Noboa, PhD, MS

Co-Investigadora

Centro de Investigación Clínica y Promoción de la Salud

UPR-Recinto de Ciencias Médicas

Identification and evaluation of SARS-CoV-2 cell entry inhibitors as novel drugs for COVID-19

 

 

Idalí Martínez Martínez, PhD

Catedrática

Departamento de Microbiología

UPR-Recinto de Ciencias Médicas

 

 

Moderadora:

Carmen S. Maldonado-Vlaar, PhD

Catedrática

Departamento de Biología y Directora de CRiiAS

UPR-Recinto de Río Piedras

 

 

Información para conectarse:

Conéctate a: https://meet.google.com/xnd-gjso-gss

 

Transmisión en directo: https://stream.meet.google.com/stream/e8eae4ba-6939-47a4-a83e-510d351a042b

Por teléfono a: (US) +1 484-551-8739 PIN: 619 341 430#

 

Este evento es abierto al público en general y libre de costos, por lo que recomendamos que se conecte por

los menos 15 minutos antes de que comience la transmisión por Google Meet.

Para mayor información: criias.degi@upr.edu/zobeida.diaz@upr.edu

 

 

Publication Date: 
11/04/2020

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020

NEWS

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020

 

https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6944e3-H.pdf

 

Summary

 

What is already known about this topic?

Limited information suggests that pregnant women with COVID-19 might be at increased risk for severe illness compared with nonpregnant women.

 

What is added by this report?

In an analysis of approximately 400,000 women aged 15–44 years with symptomatic COVID-19, intensive care unit admission, invasive ventilation, extracorporeal membrane oxygenation, and death were more likely in pregnant women than in nonpregnant women.

 

What are the implications for public health practice?

Pregnant women should be counseled about the risk for severe COVID-19–associated illness including death; measures to prevent infection with SARS-CoV-2 should be emphasized for pregnant women and their families. These findings can inform clinical practice, risk communication, and medical countermeasure allocation.

 

 

Publication Date: 
11/04/2020

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020

NEWS

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020

https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6944e3-H.pdf

Summary
What is already known about this topic?

Limited information suggests that pregnant women with COVID-19 might be at increased risk for severe illness compared with nonpregnant women.

What is added by this report?

In an analysis of approximately 400,000 women aged 15–44 years with symptomatic COVID-19, intensive care unit admission, invasive ventilation, extracorporeal membrane oxygenation, and death were more likely in pregnant women than in nonpregnant women.

What are the implications for public health practice?

Pregnant women should be counseled about the risk for severe COVID-19–associated illness including death; measures to prevent infection with SARS-CoV-2 should be emphasized for pregnant women and their families. These findings can inform clinical practice, risk communication, and medical countermeasure allocation.

Publication Date: 
11/04/2020

Pages